Voyager Therapeutics Climb 19%, Extending Rally on Novartis Pact

On Tuesday, Voyager shares surged as much as 39% after the company said it will receive $100 million up front as part of a license pact with Novartis that includes a $20 million purchase of newly issued equity in Voyager. Voyager will also be eligible to get as much as $1.2 billion in preclinical, development and regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids.

Under the deal, Novartis will get a target-exclusive license to access Voyager’s TRACER capsids and other intellectual property for Huntington’s disease and spinal muscular atrophy. The two companies will collaborate to advance a preclinical gene therapy candidate for Huntington’s disease, according to a press release.